Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | DRD5 | P21918 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666098 | 1.00 | ACE (0.67) | ACECYP19A1ACHEDRD5MMP3 | |
| SCHEMBL677552 | 1.00 | ACE (0.67) | ACECYP19A1ACHEDRD5MMP3 | |
| SCHEMBL8243497 | 1.00 | ACE (0.67) | ACECYP19A1ACHEDRD5MMP3 | |
| SCHEMBL26312410 | 0.91 | CYP19A1 (0.57) | ACECYP19A1ACHEMEN1KMT2A | |
| SCHEMBL16265990 | 0.90 | CYP19A1 (0.56) | ACECYP19A1ACHEMEN1KMT2A | |
| SCHEMBL24380346 | 0.89 | CYP19A1 (0.72) | CYP19A1 | |
| SCHEMBL25756464 | 0.89 | CYP19A1 (0.72) | CYP19A1 | |
| SCHEMBL29582353 | 0.89 | CYP19A1 (0.72) | CYP19A1 | |
| SCHEMBL16750308 | 0.89 | CYP19A1 (0.72) | CYP19A1 | |
| SCHEMBL15112500 | 0.88 | ACHE (0.57) | ACECYP19A1ACHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112010937-B | YIGSR modified pentacyclic piperazinedione and preparation and application thereof | 首都医科大学（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-112010935-B | Acetyl RGD modified hexacyclic piperazinedione, preparation, anti-tumor activity and application thereof | 首都医科大学 | 2022-08-05 | — | — | CN | claimed |
| CN-111978372-B | RGD sequence peptide modified hexacyclic piperazinedione, preparation, antitumor activity and application thereof | 首都医科大学 | 2022-08-02 | — | — | CN | claimed |
| CN-112010938-B | Acetyl RGD modified hexacyclic piperazinedione, preparation, anti-inflammatory activity and application thereof | 首都医科大学 | 2022-08-02 | — | — | CN | claimed |
| CN-112010934-B | Acetyl RGD modified hexacyclic piperazinedione, preparation, transfer-resistant activity and application thereof | 首都医科大学 | 2022-08-02 | — | — | CN | claimed |
| CN-112010855-B | Hexacyclic piperazinedione compounds, preparation, biological activity and application thereof | 首都医科大学 | 2021-06-08 | — | — | CN | claimed |
| CN-112010934-A | Acetyl RGD modified hexacyclic piperazinedione, preparation, transfer-resistant activity and application thereof | 首都医科大学 | 2020-12-01 | — | — | CN | claimed |
| CN-112010939-A | RGD sequence peptide modified hexacyclic piperazinedione, preparation, anti-inflammatory activity and application thereof | 首都医科大学 | 2020-12-01 | — | — | CN | claimed |
| CN-112010930-A | RGD modified pentacyclic piperazinedione and preparation and application thereof | 首都医科大学 | 2020-12-01 | — | — | CN | claimed |
| CN-112010937-A | YIGSR modified pentacyclic piperazinedione and preparation and application thereof | 首都医科大学 | 2020-12-01 | — | — | CN | claimed |
| CN-112010938-A | Acetyl RGD modified hexacyclic piperazinedione, preparation, anti-inflammatory activity and application thereof | 首都医科大学 | 2020-12-01 | — | — | CN | claimed |
| CN-112010855-A | Hexacyclic piperazinedione compounds, preparation, biological activity and application thereof | 首都医科大学 | 2020-12-01 | — | — | CN | claimed |
| CN-112010929-A | RGD sequence peptide modified hexacyclic piperazinedione, preparation, transfer-resistant activity and application thereof | 首都医科大学 | 2020-12-01 | — | — | CN | claimed |
| CN-112010935-A | Acetyl RGD modified hexacyclic piperazinedione, preparation, anti-tumor activity and application thereof | 首都医科大学 | 2020-12-01 | — | — | CN | claimed |
| CN-111978372-A | RGD sequence peptide modified hexacyclic piperazinedione, preparation, antitumor activity and application thereof | 首都医科大学 | 2020-11-24 | — | — | CN | claimed |
| US-20050080015-A1 | Carboline-3-carboxylic acid modified related sequences of Ala-Arg-Pro-Ala-Lys, their synthesis and use as thromobolytic agent | GUANGZHOU BAI YUN SHAN PHARMACEUTICAL CO. LTD (CN) | 2005-04-14 | — | — | US | claimed |
| US-12458627-B2 | Autotaxin inhibitors and uses thereof | DF 2024 IP ACQUISITION, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| CN-112010914-B | Glucosamine modified pentacyclic piperazine dione and preparation and application thereof | 首都医科大学 | 2023-06-27 | — | — | CN | disclosed |
| US-5162336-A | Disorders of gastrointestinal, central nervous and appetite regulatory systems | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1992-11-10 | — | — | US | disclosed |
| US-4965250-A | TETRAPEPTIDE; IMMUNE SYSTEM ACTIVATION | ADIR ET CIE (FR) | 1990-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080015-A1 | Carboline-3-carboxylic acid modified related sequences of Ala-Arg-Pro-Ala-Lys, their synthesis and use as thromobolytic agent | PEPD, PLAT, CTSL | ACE 201/4885CYP19A1 2573/4885ACHE 3150/4885 |
| US-12458627-B2 | Autotaxin inhibitors and uses thereof | ENPP2, SERPINB1, RNASE1 | ACE 442/4885CYP19A1 2934/4885ACHE 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.